Demographic and clinical characteristics of the 120 patients with RA. Values are n (%) or median (IQR).
| Characteristics | Values |
|---|---|
| Female | 95 (79) |
| Age, yrs | 52 (44–61) |
| Disease duration, mos | 48 (12–120) |
| Core disease activity indicators | |
| 28-TJC | 9 (3–15) |
| 28-SJC | 4 (2–9) |
| PtGA | 6 (4–7) |
| PrGA | 6 (4–7) |
| ESR, mm/h | 68 (30–92) |
| Elevated ESR* | 108 (90) |
| CRP, mg/l | 24 (7–53) |
| Elevated CRP** | 97 (81) |
| RF-positive rate | 83 (69) |
| ACPA-positive rate | 83 (69) |
| DAS28-CRP | 5.9 (4.7–6.9) |
| SDAI | 29 (18–42) |
| CDAI | 26 (16–36) |
| HAQ score | 1 (0–2) |
| Radiographic assessment | |
| mTSS | 36 (15–66) |
| Joint space narrowing subscore | 5 (1–20) |
| Erosion subscore | 26 (11–43) |
| Bony erosions | 116 (97) |
| Radiographic joint damage, mTSS > 10 | 95 (79) |
| Previous medications | |
| DMARD- and corticosteroid-naive | 70 (58) |
| Low-dose glucocorticoid alone | 14 (12) |
| Low-dose glucocorticoid + DMARD | 25 (21) |
| DMARD alone | 11 (9) |
↵* Elevated ESR: > 15 mm/h for males and > 20 mm/h for females.
↵** Elevated CRP: CRP > 5 mg/l. IQR: interquartile range; 28-TJC: 28-joint tender joint count; 28-SJC: 28-joint swollen joint count; PtGA: patient’s global assessment of disease activity; PrGA: provider global assessment of disease activity; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; ACPA: anticyclic citrullinated peptide antibody; DAS28: 28-joint count Disease Activity Score; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; mTSS: modified total Sharp/van der Heijde score; DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis.